Saxenda versus Wegovy: liraglutide and semaglutide are not the same prescription

Saxenda and Wegovy are different FDA-approved finished products: Saxenda contains liraglutide in a daily injection, while Wegovy’s weight-management injection contains semaglutide on a weekly schedule. In the 68-week STEP 8 randomized trial in adults with overweight or obesity without diabetes, studied weekly semaglutide produced greater average weight reduction than studied daily liraglutide. That population result is not a personal outcome forecast, a reason to combine drugs, or evidence that every Wegovy formulation has the same age indication.¹²³

Read the two cartons before reading the headline

The shared GLP-1 receptor-agonist family does not make liraglutide and semaglutide interchangeable. Saxenda’s current label identifies its daily injectable form and weight-reduction indications for adults and certain adolescents 12 and older. The Wegovy label includes a weekly injectable form with adolescent obesity labeling, but also a tablet whose pediatric safety and effectiveness are not established. A comparison should specify injection versus injection unless it explicitly discusses the tablet.¹²

Both labels contain important contraindications and warnings, including the boxed warning concerning thyroid C-cell tumors seen in rodents and contraindications involving personal or family medullary thyroid carcinoma or MEN2. A clinician needs the complete personal and medication history, not just the comparative weight curve. The Saxenda label also advises against coadministration with another GLP-1 receptor agonist; a switch or overlap cannot be planned from an online schedule.¹²

What STEP 8 can support

STEP 8 directly randomized 338 adults without diabetes to studied semaglutide, liraglutide, or placebo regimens alongside counseling on diet and activity. At 68 weeks, the reported mean body-weight change was about −15.8% with semaglutide and −6.4% with liraglutide under that trial’s analysis. It is fair to say the studied semaglutide regimen outperformed the studied liraglutide regimen on average in that specific adult population. It is not fair to turn those numbers into what a person will lose, to apply them unmodified to adolescents or diabetes populations, or to claim one product is universally appropriate.³

Practical access matters too. The labels cannot establish today’s local stock, insurance coverage, or an individual quote. Ask the practice and pharmacy to confirm the actual product being prescribed, how coverage is checked, and who owns follow-up if access changes. Do not buy a look-alike or compounded product under the assumption that STEP 8 studied it; the trial compared specified finished injectable medicines.

The appointment question

Why might someone still discuss Saxenda despite STEP 8’s average result? The trial is one important outcome measure, but a finished-product decision also includes the label’s indication, contraindications, tolerability, daily-versus-weekly routine, care continuity, and real access. A clinician may find a product inappropriate for reasons unrelated to average efficacy. Conversely, a marketing page should not hide a direct comparison merely because both drugs belong to the same family. The better consultation names which evidence applies and which factors remain personal.¹²³

The adolescent comparison is narrower still. Both injection labels include pediatric obesity language, but STEP 8 enrolled adults without diabetes. It cannot rank the products for every teen. The Saxenda label also has a body-weight criterion for its pediatric indication; the Wegovy injection label uses an obesity criterion tied to age and sex. A prescriber evaluating an adolescent should read those exact labels and pediatric evidence rather than transplant the adult head-to-head result.¹²

“Given my indication and history, which exact product and formulation are you proposing, and why does its label fit? How do the trial’s population and the product’s warnings relate to me? What is the follow-up plan?” The four-brand label guide explains neighboring brand distinctions, and the Wegovy adolescent guide handles a separate pediatric decision. Use Treomark’s medical weight-management hub to compare consultation access—not to infer a best drug or provider ranking.